Posted by Michael Wonder on 05 May 2018
Long term benefit of neuroblastoma treatment is too uncertain, says NICE
4 May 2018 - NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.
Evidence suggests dinutuximab beta (Qarziba, EUSA Pharma) could increase overall survival compared with current treatment, but there is still substantial uncertainty about its long-term benefits.
Because dinutuximab beta has promising clinical benefit, the NICE appraisal committee would like to recommend it for managed access in the Cancer Drugs Fund. However, for it to be able to do so, the company will need to reconsider the cost of the treatment to the NHS.
